Chondrosarcoma clinical trials
12 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
- A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
- Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
- Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
- Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing
- Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
- Understanding Engagement Trends in Chondrosarcoma Clinical Trials
- A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
- Long-Term Longitudinal QoL in Patients Undergoing EEA
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Chondrosarcoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.